The US Centers for Disease Control and Prevention (CDC) has reported a significant decline in cervical precancer rates among young women, particularly those who received the human papillomavirus (HPV) vaccine at routine ages. Data from 2008 to 2022 show that cervical intraepithelial neoplasia (CIN) grades 2-3 and adenocarcinoma in situ (AIS), defined as CIN2+, decreased by 79%, while CIN grade 3 and AIS, defined as CIN3+, dropped by 80%. This decline is consistent with the impact of HPV vaccination, which has been shown to prevent cervical precancers among women aged 20-29. The CDC’s National Center for Immunization and Respiratory Diseases found that most women in this age group had been vaccinated at age 11-12, leading to a decrease in CIN3+ incidence before CIN2+. While the study has limitations, the trend analysis suggests that HPV vaccination has a significant impact on preventing cervical precancers.
Source: https://www.medpagetoday.com/hematologyoncology/cervicalcancer/114412